Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP - 1 Jul 2024

ElShereef Cherine E, Zaki Hala F, Badary Osama A, Kamal Sherif, Nagy Mohamed, Makhlouf Dalia, Kamal Mohamed, Elnadi Inas, A Abdelshafi Sameh, Abou El Naga Sherif, Saber Mona M

Abstract excerpt

OBJECTIVES: Rhabdomyosarcoma (RMS) accounts for 50% of soft tissue sarcomas and 7% of pediatric malignancies. Cyclophosphamide (CPA) is the cornerstone of therapy and is a prodrug that is activated by the highly polymorphic drug-metabolizing enzyme CYP3A5. We aim to examine the possible CYP3A5 polymorphism association with CPA efficacy, survival outcomes, and toxicity in Egyptian pediatric RMS patients. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Follow-Up Studies

Share to Prognosis

Share to Rhabdomyosarcoma

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 39068579
DOI: 10.31557/APJCP.2024.25.7.2445
PMCID: PMC11480601

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.PMID 39068579Read ↗

Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.Semantic proximity Read ↗

CYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with Cyclophosphamide.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.Semantic proximity Read ↗

Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity Read ↗

Analysis of CYP450 gene allelic variants can predict ifosfamide toxicity in Mexican paediatric patients.Semantic proximity Read ↗

Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.Semantic proximity Read ↗

Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Semantic proximity Read ↗

CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.Semantic proximity Read ↗

Exploring the Correlation Between Genotypes of Drug-Metabolizing Enzymes and the Therapeutic Efficacy and Adverse Reactions of Cyclophosphamide in Childhood-Onset Lupus Nephritis: A Chinese Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.